{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:14Z","timestamp":1786119374849,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/iae.0b013e3181b32d13","type":"journal-article","created":{"date-parts":[[2009,11,3]],"date-time":"2009-11-03T03:19:15Z","timestamp":1257218355000},"page":"1404-1408","source":"Crossref","is-referenced-by-count":10,"title":["VASCULAR EVENTS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAOCULAR BEVACIZUMAB"],"prefix":"10.1097","volume":"29","author":[{"given":"ARSHAM","family":"SHEYBANI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEVEN","family":"KYMES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHELLEY","family":"SCHLIEF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RAJENDRA","family":"APTE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210130","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archopht.121.11.1621","article-title":"Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.","volume":"121","author":"Bressler","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R2-3-20210130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States.","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R3-3-20210130","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy.","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R4-3-20210130","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-3-20210130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-3-20210130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R7-3-20210130","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1055\/s-2006-926875","article-title":"[Early effects of systemic and intravitreal bevacizumab (Avastin) therapy for neovascular age-related macular degeneration].","volume":"223","author":"Geitzenauer","year":"2006","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R8-3-20210130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00417-006-0466-4","article-title":"Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.","volume":"245","author":"Lazic","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-3-20210130","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.ophtha.2006.05.070","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.","volume":"113","author":"Moshfeghi","year":"2006","journal-title":"Ophthalmology"},{"key":"R10-3-20210130","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/01.iae.0000244380.34082.67","article-title":"Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.","volume":"26","author":"Yoganathan","year":"2006","journal-title":"Retina"},{"key":"R11-3-20210130","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R12-3-20210130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R13-3-20210130","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R14-3-20210130","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/archopht.1992.01080240041025","article-title":"Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group.","volume":"110","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R15-3-20210130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/oxfordjournals.aje.a009421","article-title":"Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study.","volume":"47","author":"Klein","year":"1998","journal-title":"Am J Epidemiol"},{"key":"R16-3-20210130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archopht.1995.01100060069034","article-title":"Dietary fat and age-related maculopathy.","volume":"113","author":"Mares-Perlman","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"R17-3-20210130","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/archopht.119.9.1259","article-title":"Body mass index and the incidence of visually significant age-related maculopathy in men.","volume":"119","author":"Schaumberg","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R18-3-20210130","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ophtha.2006.07.045","article-title":"Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans.","volume":"114","author":"Duan","year":"2007","journal-title":"Ophthalmology"},{"key":"R19-3-20210130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R20-3-20210130","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archopht.122.5.716","article-title":"Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13.","volume":"122","author":"Clemons","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R21-3-20210130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/14796694.3.2.141","article-title":"Bevacizumab in the treatment of metastatic colorectal cancer.","volume":"3","author":"Caprioni","year":"2007","journal-title":"Future Oncol"},{"key":"R22-3-20210130","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMcp071137","article-title":"Clinical practice. Isolated systolic hypertension in the elderly.","volume":"357","author":"Chobanian","year":"2007","journal-title":"N Engl J Med"},{"key":"R23-3-20210130","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.ophtha.2007.09.017","article-title":"Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients.","volume":"114","author":"Alexander","year":"2007","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-200911000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:05:31Z","timestamp":1786039531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200911000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3181b32d13","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}